EPA reduces inflammation and cuts cardiovascular death by 20%. DHA builds your brain. Most people are deficient in both — and taking the wrong form absorbs 70% less. Here is what the evidence actually says.
Omega-3 fatty acids are not interchangeable. EPA and DHA are chemically distinct long-chain polyunsaturated fats with different tissue distributions, different enzymatic fates, and different clinical effects. Treating them as identical — as most supplement marketing does — misses the entire point.
Eicosapentaenoic acid (EPA, 20:5n-3) is the body's primary anti-inflammatory omega-3. Its dominant mechanism is substrate competition: EPA and arachidonic acid (ARA, the omega-6 precursor of pro-inflammatory eicosanoids) share the same enzymatic machinery — COX-1, COX-2, and the LOX enzymes. When EPA occupies these enzymes, less inflammatory prostaglandin E2, thromboxane A2, and leukotriene B4 are produced.
But EPA does more than block. It generates a family of specialized pro-resolving mediators (SPMs) — specifically resolvins (RvE series) and protectins — that actively turn off inflammation. This is a qualitatively different action from simply blocking inflammatory signaling. Resolvins signal neutrophils to stop migrating into tissue and promote macrophage clearance of cellular debris. This is inflammation resolution, not suppression.
EPA also directly reduces serum triglycerides by inhibiting hepatic VLDL synthesis and increasing triglyceride clearance via lipoprotein lipase. At 2-4g/day, EPA lowers triglycerides by 20-50% depending on baseline levels — one of the most robust dose-response relationships in nutritional pharmacology.
Docosahexaenoic acid (DHA, 22:6n-3) is not primarily a signaling molecule — it is the brain's primary structural fat. DHA constitutes approximately 40% of the polyunsaturated fatty acids in brain gray matter phospholipids. It is also the dominant fatty acid in retinal photoreceptor membranes, where its six double bonds create the membrane fluidity that enables the rapid conformational changes in rhodopsin required for phototransduction.
In neurons, DHA's extreme flexibility (it can rotate through 10^7 conformations per second) makes synaptic membranes fluid enough for neurotransmitter receptors to cluster efficiently and for ion channels to open rapidly. Rigid, saturated-fat-dominated membranes slow synaptic signaling. DHA-rich membranes support fast, efficient neural transmission.
DHA is also a precursor to its own class of SPMs — DHA-derived resolvins (RvD series) and protectins (especially neuroprotectin D1, NPD1), which are particularly active in the brain and retina. NPD1 has been shown to protect neurons from oxidative stress-induced apoptosis and to suppress the amyloid-beta and tau pathology that drives Alzheimer's disease in cell and animal models.
The central nutritional problem of the modern diet is not a deficiency of any single nutrient — it is the profound disruption of the omega-6 to omega-3 ratio. Hunter-gatherer populations ate a ratio of approximately 1:1 to 2:1 (omega-6:omega-3). Epidemiological evidence suggests a ratio below 4:1 is associated with substantially lower rates of cardiovascular disease and inflammatory conditions.
The modern Western diet, dominated by seed oils (soybean, corn, sunflower, canola) and minimal fatty fish consumption, has pushed this ratio to 15:1 to 20:1. The consequences are mechanistically predictable: with 15-20x more arachidonic acid substrate available than EPA, the COX and LOX enzymes produce overwhelmingly pro-inflammatory metabolites. Every meal rich in seed oils further tilts the balance toward the inflammatory phenotype.
Correcting this ratio requires two interventions working in parallel: reducing linoleic acid intake (the omega-6 precursor) by cutting processed foods and seed oils, and supplementing EPA+DHA to directly increase the omega-3 pool. Supplementation alone is insufficient without dietary change; dietary change alone, without fatty fish consumption, rarely achieves optimal tissue ratios.
Two major randomized controlled trials put omega-3 cardiovascular benefits to the test — and produced contradictory results that changed how clinicians think about fish oil. Understanding the difference explains why supplement form and purity matter enormously.
The REDUCE-IT trial enrolled 8,179 high-risk patients already on statin therapy with elevated triglycerides (135-500 mg/dL) and randomized them to 4g/day of icosapentaenoic acid ethyl ester (Vascepa — pure EPA) or mineral oil placebo. Median follow-up was 4.9 years.
The results were striking enough to land on the front page of the New England Journal of Medicine. The primary composite endpoint — cardiovascular death, nonfatal MI, nonfatal stroke, coronary revascularization, or unstable angina — was reduced by 25% (HR 0.75, 95% CI 0.68-0.83, p<0.001). Cardiovascular death specifically fell by 20% (HR 0.80). Fatal MI was reduced by 31%.
The magnitude of benefit was large enough that the FDA approved icosapentaenoic acid (as Vascepa) specifically for cardiovascular risk reduction — the first omega-3 to receive this indication. The number needed to treat (NNT) to prevent one major cardiovascular event over five years was approximately 21, comparable to some statins.
One year after REDUCE-IT's triumph, the STRENGTH trial published its results — and threw the field into confusion. STRENGTH enrolled 13,078 high-risk patients and randomized them to 4g/day of a combined EPA+DHA carboxylic acid formulation (Epanova) or corn oil placebo. The primary endpoint was identical to REDUCE-IT.
STRENGTH was terminated early for futility. There was no cardiovascular benefit (HR 0.99, 95% CI 0.90-1.09). Zero. A virtually identical intervention — high-dose omega-3 in high-risk patients on statins — produced diametrically opposite results.
Why? Several hypotheses have been proposed, none definitive:
The practical implication: for cardiovascular risk reduction specifically, pure EPA supplements appear superior to mixed EPA+DHA. For other goals — brain health, mood, inflammation — mixed EPA+DHA remains the standard of evidence.
| Trial | Intervention | N | Primary Outcome | Result | Evidence Grade |
|---|---|---|---|---|---|
| REDUCE-IT (2018) | 4g/day pure EPA (Vascepa) | 8,179 | MACE composite | −25% RRR, −20% CV mortality | RCT · A |
| STRENGTH (2020) | 4g/day EPA+DHA (Epanova) | 13,078 | MACE composite | No benefit (HR 0.99) | RCT · A |
| Mocking 2016 (meta-analysis) | EPA supplementation for depression | ~1,200 | Depressive symptoms (HAM-D) | EPA > DHA; min 1g EPA/day effective | Meta-Analysis · A |
| VITAL (2019) | 1g/day EPA+DHA (Omacor) | 25,871 | CV events + cancer | −28% MI in fish non-consumers | RCT · A |
| ORIGIN (2012) | 1g/day EPA+DHA | 12,536 | CV outcomes, diabetes | Neutral (low-dose, low TG baseline) | RCT · B |
| Observational (Fish Intake) | High fish consumption cohorts | Multiple | Alzheimer's incidence | 30-50% lower risk vs. low fish intake | Observational · B |
The brain is approximately 60% fat by dry weight, and DHA is its most abundant polyunsaturated fatty acid. This is not incidental — the brain selectively accumulates DHA from the bloodstream with extreme efficiency, and DHA depletion has measurable effects on synaptic function, neurogenesis, and mood regulation.
Brain-derived neurotrophic factor (BDNF) is the brain's primary growth and maintenance factor — it promotes neurogenesis in the hippocampus, strengthens synaptic connections, and supports the survival of existing neurons. Low BDNF is consistently observed in depression, cognitive decline, and Alzheimer's disease.
DHA and BDNF have a bidirectional relationship. DHA supplementation upregulates BDNF mRNA expression in the hippocampus in animal models. BDNF in turn promotes DHA uptake into neuronal membranes. Both are upregulated by aerobic exercise. The practical implication is that DHA supplementation and exercise are synergistic for neuroplasticity — their combination produces greater BDNF elevation than either alone.
For mood specifically, EPA appears to be the critical omega-3. The landmark 2016 meta-analysis by Mocking et al. pooled data from randomized controlled trials of omega-3 supplementation for major depressive disorder. The key finding: EPA-dominant preparations were effective antidepressants; DHA-dominant preparations were not.
Preparations with a higher EPA:DHA ratio (particularly those providing at least 1g/day of EPA) showed effect sizes comparable to second-generation antidepressants, especially in patients with elevated inflammatory markers. EPA was approximately three times more effective than DHA for depressive symptom reduction. A minimum of 1g EPA/day appears to be the threshold for measurable antidepressant effect.
The proposed mechanisms include EPA's anti-inflammatory effects on neuroinflammation (increasingly recognized as a driver of depression in a subset of patients), EPA's role in serotonin receptor function, and EPA-derived SPMs reducing microglial overactivation that impairs hippocampal neurogenesis.
DHA depletion is a consistent neuropathological finding in Alzheimer's disease brains — postmortem studies show DHA levels in frontal cortex phospholipids are significantly lower in Alzheimer's patients than age-matched controls. Whether this is cause or consequence remains debated, but the evidence tilts toward causal.
Large cohort studies — including the Framingham Heart Study — show that individuals in the highest quartile of DHA blood levels have a 47% lower risk of developing Alzheimer's over 9 years compared to the lowest quartile. High fish consumption (2+ servings per week) in mid-life is associated with 30-50% lower Alzheimer's incidence in most prospective cohort studies.
Intervention trials in already-diagnosed Alzheimer's have been largely disappointing, suggesting (as with most neuroprotective strategies) that timing matters: DHA's protective effects are preventive, not therapeutic once significant neurodegeneration has occurred. The optimal window appears to be midlife, before amyloid accumulation becomes symptomatic.
Not all fish oil is created equal. The molecular form in which EPA and DHA are packaged determines how much reaches your bloodstream — differences of 50-70% in bioavailability separate the best and worst forms. Understanding this prevents buying expensive supplements that deliver a fraction of their labeled dose.
In wild-caught fatty fish, EPA and DHA are bound in the natural triglyceride form — two fatty acids esterified to a glycerol backbone (sn-2 position is typically the omega-3). This is the form the digestive system is optimized for: pancreatic lipase cleaves the sn-1 and sn-3 positions efficiently, releasing EPA and DHA for absorption.
Natural triglyceride fish oils and high-quality re-esterified triglyceride (rTG) supplements — where the fatty acids have been enzymatically reattached to glycerol after concentration — absorb 50-70% better than ethyl ester form in both fasted and fed states. They are more expensive to produce, which is why most mass-market fish oil uses ethyl ester instead.
Ethyl ester (EE) is the most common commercial fish oil form, including prescription-grade Lovaza. In this form, the fatty acids are esterified to ethanol rather than glycerol. The body must first cleave the ethyl ester bond and then re-esterify to glycerol for absorption — an inefficient process particularly in the absence of dietary fat.
Bioavailability of EE fish oil is substantially lower than TG form, especially in a fasted state. Taking EE fish oil without a fat-containing meal can reduce absorption by up to 50% compared to taking it with a meal. Even with food, TG-form oil maintains an absorption advantage. This matters when comparing labels: a "1000mg fish oil" capsule in EE form delivers meaningfully less EPA+DHA to tissues than the same dose in TG form.
Krill oil binds EPA and DHA to phosphatidylcholine rather than triglycerides or ethyl esters. This form may offer superior brain delivery because phospholipid-bound omega-3s can cross the blood-brain barrier via a dedicated phospholipid transport pathway. Krill oil also contains astaxanthin — a marine carotenoid with potent antioxidant properties that protects the omega-3s from oxidation and may have independent anti-inflammatory effects.
The drawback: krill oil contains lower concentrations of EPA+DHA per gram compared to concentrated fish oil. To achieve therapeutic doses (2-4g EPA+DHA/day), krill oil becomes expensive and requires large capsule counts. Krill oil excels for maintenance dosing and brain-specific goals; concentrated TG fish oil is more practical for therapeutic cardiovascular dosing.
Marine algae are the original source of omega-3s — fish accumulate EPA and DHA by eating algae and algae-eating zooplankton. Algae-derived oil bypasses the fish entirely, providing DHA (and in some formulations, EPA) directly from the photosynthetic source. This makes it the only truly sustainable, mercury-free, and vegan-compatible omega-3 source.
Algae DHA bioavailability matches fish oil DHA in controlled studies. The limitation has historically been low EPA content, though newer algae strains and extraction processes are producing higher-EPA algae oils. For vegans seeking primarily DHA for brain and structural health, algae oil is a scientifically sound choice that removes all concerns about heavy metals, PCBs, and fishing sustainability.
| Form | Bioavailability | EPA Content | DHA Content | Best For | Notes |
|---|---|---|---|---|---|
| Natural TG | Excellent | High | High | General use, cardiovascular | Less concentrated than EE |
| Re-esterified TG | Excellent | Very High | Very High | High-dose therapeutic | Best form for concentrated supplements |
| Ethyl Ester | Moderate | Very High | Very High | Budget, Rx Lovaza/Vascepa | Take with fatty meal. Most common form. |
| Phospholipid (Krill) | Superior (brain) | Moderate | Moderate | Brain health, maintenance | Contains astaxanthin; expensive per gram |
| Algae Oil | Good | Low–Moderate | High | Vegans, sustainability | Mercury-free, no fish smell |
Omega-3 fatty acids are highly polyunsaturated — their multiple double bonds make them prone to oxidative degradation. Rancid fish oil not only tastes and smells foul; oxidized lipids may have pro-inflammatory effects that partially negate the anti-inflammatory benefits of fresh EPA and DHA.
The international TOTOX (total oxidation) value measures primary oxidation (peroxide value) and secondary oxidation (anisidine value). The Global Organization for EPA and DHA Omega-3s (GOED) recommends TOTOX below 26. Many retail fish oils — particularly those sold in bulk at warehouse stores — exceed this threshold by the time consumers purchase them.
Omega-3 dose requirements vary significantly by therapeutic goal. The label on a fish oil bottle typically shows total fish oil weight — not the EPA+DHA content. A "1000mg fish oil" capsule may contain only 300mg of combined EPA+DHA. Read the nutrition facts to find the actual EPA+DHA per serving.
1g combined EPA+DHA per day. This can be achieved with 2-3 standard fish oil capsules depending on concentration. This dose is sufficient to modestly improve omega-3 index (a measure of EPA+DHA in red blood cell membranes) and maintain basic anti-inflammatory balance. Note: VITAL trial at this dose showed benefit only in fish non-consumers — suggesting baseline diet matters.
2-4g EPA+DHA per day, ideally as pure EPA if following the REDUCE-IT protocol. For triglyceride reduction specifically, 2-4g EPA+DHA consistently lowers triglycerides 20-50%. At these doses, physician oversight is appropriate as high-dose omega-3 can mildly increase LDL-C in some individuals and may affect anticoagulant activity.
Minimum 1g EPA/day, with a ratio of at least 2:1 EPA:DHA. Many clinical trials showing antidepressant effects used 1-2g EPA specifically. Choose high-EPA fish oil concentrates. Some practitioners use 2-3g EPA/day for treatment-resistant depression in adjunction with standard antidepressants — several RCTs support this as augmentation strategy.
500mg-1g DHA/day for cognitive maintenance and neuroprotection. For active brain health goals, 1-2g DHA combined with adequate EPA (for anti-inflammatory support) is a reasonable target. Algae oil is an excellent DHA source for this goal and provides the added benefit of phospholipid-bound delivery in some formulations.
All forms of omega-3 absorb better with a fat-containing meal — particularly important for ethyl ester forms (up to 2x improvement). Fish oil capsules can be taken with any meal containing fat. Enteric-coated formulations reduce fishy burps but may also reduce absorption in some individuals. Splitting doses across two meals (morning and evening) maintains more stable plasma levels than a single large dose.
Evidence-based recommendations by goal
As an Amazon Associate, StackProtocol earns from qualifying purchases. We only recommend products meeting our evidence standards.
As an Amazon Associate, StackProtocol earns from qualifying purchases.